FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059097302> ?p ?o ?g. }

• W2059097302 endingPage "30" @default.
• W2059097302 startingPage "24" @default.
• W2059097302 abstract "AbstractIntroduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results.Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils > 1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times.Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction < 60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died.Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.Key Words: amyloidamyloidosisanthracyclinecardiomyopathychemotherapynephrotic syndrome" @default.
• W2059097302 created "2016-06-24" @default.
• W2059097302 creator A5000879635 @default.
• W2059097302 creator A5007148032 @default.
• W2059097302 creator A5009044758 @default.
• W2059097302 creator A5012884078 @default.
• W2059097302 creator A5023193953 @default.
• W2059097302 creator A5072502164 @default.
• W2059097302 creator A5076611748 @default.
• W2059097302 creator A5080444901 @default.
• W2059097302 creator A5085821633 @default.
• W2059097302 date "2002-01-01" @default.
• W2059097302 modified "2023-10-04" @default.
• W2059097302 title "A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)" @default.
• W2059097302 cites W146910030 @default.
• W2059097302 cites W156595675 @default.
• W2059097302 cites W1998468541 @default.
• W2059097302 cites W2047427804 @default.
• W2059097302 cites W2069078219 @default.
• W2059097302 cites W2072980596 @default.
• W2059097302 cites W2094273018 @default.
• W2059097302 cites W2151953595 @default.
• W2059097302 cites W2270960065 @default.
• W2059097302 cites W2332241363 @default.
• W2059097302 cites W2336088543 @default.
• W2059097302 cites W2357045845 @default.
• W2059097302 cites W4211151727 @default.
• W2059097302 cites W4255746943 @default.
• W2059097302 doi "https://doi.org/10.3109/13506120209072441" @default.
• W2059097302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12000194" @default.
• W2059097302 hasPublicationYear "2002" @default.
• W2059097302 type Work @default.
• W2059097302 sameAs 2059097302 @default.
• W2059097302 citedByCount "58" @default.
• W2059097302 countsByYear W20590973022012 @default.
• W2059097302 countsByYear W20590973022013 @default.
• W2059097302 countsByYear W20590973022015 @default.
• W2059097302 countsByYear W20590973022017 @default.
• W2059097302 countsByYear W20590973022018 @default.
• W2059097302 countsByYear W20590973022020 @default.
• W2059097302 countsByYear W20590973022022 @default.
• W2059097302 crossrefType "journal-article" @default.
• W2059097302 hasAuthorship W2059097302A5000879635 @default.
• W2059097302 hasAuthorship W2059097302A5007148032 @default.
• W2059097302 hasAuthorship W2059097302A5009044758 @default.
• W2059097302 hasAuthorship W2059097302A5012884078 @default.
• W2059097302 hasAuthorship W2059097302A5023193953 @default.
• W2059097302 hasAuthorship W2059097302A5072502164 @default.
• W2059097302 hasAuthorship W2059097302A5076611748 @default.
• W2059097302 hasAuthorship W2059097302A5080444901 @default.
• W2059097302 hasAuthorship W2059097302A5085821633 @default.
• W2059097302 hasConcept C126322002 @default.
• W2059097302 hasConcept C126894567 @default.
• W2059097302 hasConcept C159654299 @default.
• W2059097302 hasConcept C168563851 @default.
• W2059097302 hasConcept C203014093 @default.
• W2059097302 hasConcept C2775934546 @default.
• W2059097302 hasConcept C2775965419 @default.
• W2059097302 hasConcept C2778198053 @default.
• W2059097302 hasConcept C2779551797 @default.
• W2059097302 hasConcept C2779951007 @default.
• W2059097302 hasConcept C2780306776 @default.
• W2059097302 hasConcept C2992435398 @default.
• W2059097302 hasConcept C36394416 @default.
• W2059097302 hasConcept C71924100 @default.
• W2059097302 hasConcept C78085059 @default.
• W2059097302 hasConcept C90924648 @default.
• W2059097302 hasConceptScore W2059097302C126322002 @default.
• W2059097302 hasConceptScore W2059097302C126894567 @default.
• W2059097302 hasConceptScore W2059097302C159654299 @default.
• W2059097302 hasConceptScore W2059097302C168563851 @default.
• W2059097302 hasConceptScore W2059097302C203014093 @default.
• W2059097302 hasConceptScore W2059097302C2775934546 @default.
• W2059097302 hasConceptScore W2059097302C2775965419 @default.
• W2059097302 hasConceptScore W2059097302C2778198053 @default.
• W2059097302 hasConceptScore W2059097302C2779551797 @default.
• W2059097302 hasConceptScore W2059097302C2779951007 @default.
• W2059097302 hasConceptScore W2059097302C2780306776 @default.
• W2059097302 hasConceptScore W2059097302C2992435398 @default.
• W2059097302 hasConceptScore W2059097302C36394416 @default.
• W2059097302 hasConceptScore W2059097302C71924100 @default.
• W2059097302 hasConceptScore W2059097302C78085059 @default.
• W2059097302 hasConceptScore W2059097302C90924648 @default.
• W2059097302 hasIssue "1" @default.
• W2059097302 hasLocation W20590973021 @default.
• W2059097302 hasLocation W20590973022 @default.
• W2059097302 hasOpenAccess W2059097302 @default.
• W2059097302 hasPrimaryLocation W20590973021 @default.
• W2059097302 hasRelatedWork W1964884830 @default.
• W2059097302 hasRelatedWork W1997370299 @default.
• W2059097302 hasRelatedWork W2011953819 @default.
• W2059097302 hasRelatedWork W2250087689 @default.
• W2059097302 hasRelatedWork W2590888942 @default.
• W2059097302 hasRelatedWork W2594655011 @default.
• W2059097302 hasRelatedWork W2767776988 @default.
• W2059097302 hasRelatedWork W3031400964 @default.
• W2059097302 hasRelatedWork W3153481687 @default.
• W2059097302 hasRelatedWork W4230065444 @default.

• next